GlobeNewswire PharmaceuticalsQwen · 实盘不做把握 1/10不做原因:不是事件
北京时间·🕒 发布 19:15:00·⟳ 抓取 19:15:50·⚡ 决策 09-01 19:17:59 +2m09s·55.9 天前
Kura Oncology宣布管理层将参加9月三场投资者会议
投资者会议参加公告是上市公司例行IR日程安排，不含任何新增临床数据、监管进展、合作、财务或产品催化剂，无方向、无增量信息、无可交易的edge
📄 原文GlobeNewswire Pharmaceuticals↗ 原文
Kura Oncology to Participate in Three Investor Conferences in September
SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused o…
不做 Kura Oncology（KURA.US）
投资者会议参加公告是例行IR日程通知，不含任何新催化剂（无临床数据、无监管进展、无合作、无财务信息），无交易方向和edge
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Kura Oncology发布GlobeNewswire通稿，宣布管理层将参加9月8日、9日和16日三场投资者会议。这是标准的IR日程公告，不披露任何新临床数据、监管决定、商业合作、财务指引或产品进展。此类公告对股价无方向性影响，不构成交易催化。
🔎 新鲜度:最早出现 2026-09-01 · 扩散 low · price-in 风险 low ↗
先例如何影响了这次决策
对本次决策的影响:无先例可供参考，但事件本身无交易方向
方向:不适用
涨幅量级:不适用
形态:不适用
原文全文
展开原文 · 1,498 字
SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that management will present at the following investor conferences:
Wells Fargo Healthcare Conference
September 8, 2026
3:45 p.m. ET / 12:45 p.m. PT
Cantor Global Healthcare Conference
September 9, 2026
9:10 a.m. ET / 6:10 a.m. PT
Morgan Stanley Global Healthcare Conference
September 16, 2026
7:45 a.m. ET / 4:45 a.m. PT
Live audio webcasts will be available in the Investors section of Kura’s website at
https://kuraoncology.com/
, with archived replays available following all three events.
About Kura Oncology
Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI® (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory
NPM1
-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website at
https://kuraoncology.com/
and follow us on
X
and
LinkedIn
.
Kura Contact
Investors and Media:
Greg Mann
858-987-4046
gmann@kuraoncology.com
Wells Fargo Healthcare Conference
September 8, 2026
3:45 p.m. ET / 12:45 p.m. PT
Cantor Global Healthcare Conference
September 9, 2026
9:10 a.m. ET / 6:10 a.m. PT
Morgan Stanley Global Healthcare Conference
September 16, 2026
7:45 a.m. ET / 4:45 a.m. PT
Live audio webcasts will be available in the Investors section of Kura’s website at
https://kuraoncology.com/
, with archived replays available following all three events.
About Kura Oncology
Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI® (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory
NPM1
-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website at
https://kuraoncology.com/
and follow us on
X
and
.
Kura Contact
Investors and Media:
Greg Mann
858-987-4046
gmann@kuraoncology.com
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。